Trial Registered

Roche adds third enicepatide Phase 3, this one testing China-only obesity data

The 300-patient trial joins two larger enicepatide studies already underway, deepening Roche's bet on its dual GLP-1/GIP agonist against Lilly, Novo and a crowded obesity field.

By AppliedXLJuly 3, 2026Trial NCT07670416

Executive Summary

Hoffmann-La Roche registered a third Phase 3 trial of enicepatide, its dual GLP-1/GIP receptor agonist, enrolling 300 patients with obesity or overweight, with or without type 2 diabetes, at three sites in China NCT07670416+1.
The new trial joins two larger enicepatide Phase 3 studies already recruiting globally, 1,600 patients in NCT07351058 and 2,000 in NCT07351045, meaning Roche now runs three concurrent pivotal-stage trials for the same molecule.
Enicepatide enters a field with at least eight named direct GLP-1-pathway comparators already in Phase 3 or later, including Eli Lilly's tirzepatide, orforglipron and retatrutide and Novo Nordisk's semaglutide and CagriSema, so this registration extends rather than reshapes the competitive map.
No effect-size, safety, or comparator data exist for enicepatide in any obesity trial to date, and the primary completion date for this trial is not until March 12, 2028.

The registration

Hoffmann-La Roche has registered a new Phase 3 trial evaluating enicepatide, a dual GLP-1/GIP receptor agonist, for chronic weight management in adults with obesity or overweight, with or without type 2 diabetes, according to the trial's ClinicalTrials.gov filing. The study, NCT07670416, is actively recruiting with a projected enrollment of 300 participants across three sites, all in China NCT07670416. Primary completion is anticipated by March 12, 2028, and the trial will test enicepatide alongside a reduced-calorie diet and increased physical activity, the standard background regimen for obesity pharmacotherapy trials. The trial started June 25, 2026, one day before it was added to the registry.

The endpoint

The registered primary endpoint is percent change from baseline in body weight at week 52. The protocol lists 37 secondary endpoints, spanning BMI, waist circumference, blood pressure, cholesterol panels, glycemic control in the type 2 diabetes subgroup, and quality-of-life scores, alongside adverse-event tracking through a 55-week safety follow-up. No endpoint results exist yet: ClinicalTrials.gov shows no posted results for this trial, and no completed, terminated, or withdrawn Phase 3 enicepatide trials exist in obesity to benchmark against. That makes this registration a program-scale signal, not a data event.

Program scope

This is not Roche's first Phase 3 trial of enicepatide. NCT07351058 is recruiting 1,600 participants with obesity and type 2 diabetes with a primary completion date of August 2028, and NCT07351045 is recruiting 2,000 participants with obesity or overweight without diabetes, completing July 2028. A fourth trial, a Phase 2 combination study pairing enicepatide with petrelintide, has not yet begun recruiting. Running three concurrent Phase 3 enicepatide trials, with this one carved out for China-only enrollment, points to Roche building geographic and population-specific data packages rather than a single global pivotal study.

The competitive field

Enicepatide is not first-in-class: it enters a GLP-1 receptor obesity field with active peer trials at the identical target, so first-in-class claims do not apply. Direct comparators already in Phase 3 or later include Eli Lilly's tirzepatide (Phase 4), orforglipron and retatrutide, Novo Nordisk's semaglutide (Phase 4) and CagriSema, AstraZeneca's elecoglipron, Structure Therapeutics' aleniglipron, and Pfizer's berobenatide. The broader GLP-1 receptor landscape shows a declining trial-initiation ratio, 245 recent trials against 981 older ones, suggesting the field is maturing rather than still expanding. Roche's own obesity trial-execution profile is rated favorable, with a landscape score of 45 and a low-risk, low-concern quadrant classification, and protocol stability for this trial is rated Stable with zero change events since registration.

Sponsor track record

Hoffmann-La Roche has completed 1,265 of 1,435 trials tracked globally, an 88.15% completion rate, with 170 terminated across its full portfolio of 1,680 trials. No FDA approval history or regulatory designation events, such as Breakthrough Therapy or Priority Review, are on record for enicepatide, meaning the regulatory pathway remains undefined at this stage. With primary completion not expected until March 12, 2028, investors have roughly 21 months before any of the three enicepatide Phase 3 trials can report data.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.